Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRAS<sup>G12D </sup>siRNA in patients with metastatic pancreatic cancer harboring a KRAS<sup>G12D</sup> mutation.
Rishi Surana, Valerie S. LeBleu, J. Jack Lee, Brandon G. Smaglo, Dan Zhao, Michael Sangmin Lee, Robert A. Wolff, Michael J. Overman, Mayela Carolina Mendt, Kathleen M. McAndrews, Sujuan Yang, Katy Rezvani, Raghu Kalluri, Anirban Maitra, Elizabeth J. Shpall, Shubham Pant
Abstract
TPS633 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with few effective therapeutic options. Over 90% of patients with PDAC harbor activating mutations in KRAS, a known oncogenic driver of tumor growth, cancer cell survival and metastasis thus making for an attractive therapeutic target. However, targeting the most common KRAS mutations in pancreatic cancer (KRAS G12D and KRAS G12V ) remains a pharmacological challenge. Exosomes are extracellular nano-vesicles that are efficiently internalized by target cells and are under investigation as a drug-delivery vehicle for various therapeutic payloads, including nucleic acids such as small interfering RNA (siRNA). Previously published pre-clinical data demonstrate effective delivery of exosomes loaded with siRNA targeting KRAS G12D leading to tumor control in various murine models of PDAC. Methods: This is a single arm, single institution, phase I trial evaluating treatment with KRAS G12D -siRNA loaded exosomes. Large-scale production of KRAS G12D -siRNA loaded exosomes from mesenchymal stromal cells will be performed at the MD Anderson Cancer Center using pre-specified GMP-compliant protocols. The primary endpoints of this study are to determine a maximum tolerated dose (MTD) of KRAS G12D -loaded exosomes and to identify dose-limiting toxicities (DLT). Key secondary endpoints include the pharmacokinetics of circulating exosomes, overall response rate, disease control rate (defined as partial responses and patients with stable disease), median progression-free survival (PFS) and median overall survival (OS). Key inclusion criteria include histologically confirmed metastatic pancreatic ductal adenocarcinoma, documented progression on one or more lines of systemic therapy, and documented presence of a KRAS G12D mutation. Selected correlative studies include measurement of circulating siRNA and KRAS G12D DNA using PCR. This trial will enroll up to 28 patients and will follow a 3+3 design for dose escalation. This trial is actively accruing and has enrolled six patients at the time of submission. Clinical trial information: NCT03608631.